Technical Briefing: Pfizer, Merck & Co., AbbVie, and Zogenix

Editor Note: For more information about this release, please scroll to bottom

LONDON, July 24, 2013 /PRNewswire/ --

On Tuesday, July 23, 2013, shares in major drug manufacturers ended on a mixed note, tracking the broader market. The major movers in the industry included Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and Zogenix Inc. (NASDAQ: ZGNX). All these companies are tracked by AAAResearchReports.com. Free technical research reports on PFE, MRK, ABBV, and ZGNX can be accessed by signing up at:

http://www.aaaresearchreports.com/register/  

Shares in Pfizer Inc. edged higher on Tuesday, extending their gains from previous trading sessions. The company's shares fluctuated between $29.32 and $29.53 before finishing the day 0.24% higher at $29.42. A total of 27.28 million shares were traded which is below the daily average volume of 79.54 million. The stock has gained 3.26% in the last three trading sessions and 3.37% in the last one month as compared to a gain of 0.18% and 6.28% in the S&P 500 during the respective periods. Download free report on PFE upon registration at:

http://www.AAAResearchReports.com/PFE072413.pdf

Merck & Co. Inc.'s stock edged higher on Tuesday, ending the session at $47.93, up 0.44% from its previous closing price. The company's shares fluctuated between $47.54 and $48.22. A total of 9.24 million shares were traded which is below the daily average volume of 15.62 million. The company's shares have gained 1.12% in the last three trading sessions and 1.98% in the last one month. MRK technical report can be accessed for free by signing up at:

http://www.AAAResearchReports.com/MRK072413.pdf

Shares in AbbVie Inc. moved lower on Tuesday, reversing all of their gains from previous trading sessions. The company's shares fluctuated between $44.23 and $45.09 before finishing the day 1.47% lower at $44.31. A total of 3.54 million shares were traded which is below the daily average volume of 4.61 million. The company's shares have fallen by 0.02% in the last three trading sessions. Despite Tuesday's pullback, the stock is trading above its 50-day and 200-day moving averages. A free report on ABBV can be accessed by registering at:

http://www.AAAResearchReports.com/ABBV072413.pdf

Zogenix Inc.'s stock fell sharply on Tuesday, extending its losses from previous trading sessions. The company's shares ended the day 1.92% lower at $1.53 after oscillating between $1.52 and $1.58. A total of 252,925 shares were traded which is below the daily average volume of 479,069. The company's shares have fallen by 5.56% in the last three trading sessions, underperforming the S&P 500. Register with AAA Research Reports and download research on ZGNX for free at:

http://www.AAAResearchReports.com/ZGNX072413.pdf

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


SOURCE AAA Research Reports

Suggested Articles

Sixteen years after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.